In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response in 21% of patients. Convergence of HER2 and ER signals on RB1 suggests that a combined pharmacological intervention directed to these targets could be synergistic. To test this approach, we combined palbociclib to block RB1, fulvestrant to block ER, and trastuzumab with pertuzumab to block HER2 in patients with HER2-positive, ER-positive breast cancer.

中文翻译：

---

曲妥珠单抗和帕妥珠单抗联合帕博西利布和氟维司群在HER2阳性，ER阳性乳腺癌（NA-PHER2）中进行新辅助治疗：一项探索性，开放性，2期研究。

在新辅助治疗中，HER2阳性和雌激素受体（ER）阳性的乳腺癌患者对HER2的阻滞加芳香酶抑制剂的使用可导致21％的患者发生病理完全缓解。RB1上HER2和ER信号的收敛表明，针对这些靶标的联合药理干预可能具有协同作用。为了测试这种方法，我们在患有HER2阳性，ER阳性的乳腺癌患者中联合使用了palbociclib来阻断RB1，氟维司群来阻断ER，以及曲妥珠单抗和pertuzumab来阻断HER2。